Endovascular Therapy for Acute Ischemic Stroke: A Comprehensive Review of Current Status

Kılıç, İsmail Doğu; Hakeem, Abdul; Marmagkiolis, Konstantinos; Paixao, Andre; Grunwald, Iris Q.; Mutlu, Deniz; Abou-Sherif, Sara; Gündoğdu, Betül; Kulaksızoğlu, Sibel; Ateş, İsmail; Wholey, Mark H.; Göktekín, Ömer; Çilingiroğlu, Mehmet

doi:10.1016/j.carrev.2018.07.010

Cited by 2 publications

(3 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Introductionmentioning

confidence: 99%

“…1 Administration of intravenous recombinant tissue-type plasminogen activator (rt-PA) and endovascular procedures is the mainstay of acute stroke treatment to obtain vessel recanalization and tissue reperfusion. 2,3 However, despite successful recanalization, not all patients achieve favorable clinical outcome. For instance, we use the term "futile recanalization," when ischemic tissue is not reperfused even in case recanalization is successful.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Blood Biomarkers of Parenchymal Damage in Ischemic Stroke Patients Treated With Revascularization Therapies

et al. 2019

View full text Add to dashboard Cite

Purpose: Postischemic reperfusion injury may exacerbate cerebral damage and capillary dysfunction, leading to brain edema (BE), hemorrhagic transformation (HT), necrosis, and injury from free radicals with subsequent infarct growth (IG). Several plasmatic biomarkers involved in the ischemic cascade have been studied in relation to radiological and clinical outcomes of reperfusion injury in ischemic stroke with heterogeneous results. This article provides a brief overview of the contribution of circulating biomarkers to the pathophysiology of parenchymal damage in ischemic stroke patients treated with revascularization therapies. Methods: We included full reports with measurements of plasma markers in patients with acute ischemic stroke treated with revascularization therapies. Findings: Our research included a large number of observational studies investigating a possible role of circulating biomarkers in the development of parenchymal damage after acute stroke treatments. To make the results clearer, we divided the review in 4 sections, exploring the relation of different biomarkers with each of the indicators of parenchymal damage (HT, BE, IG, recanalization). Discussion and conclusion: Definite conclusions are difficult to draw because of heterogeneity across studies. However, our review seems to confirm an association between some circulating biomarkers (particularly matrix metalloproteinase-9) and occurrence of parenchymal damage in ischemic stroke patients treated with revascularization therapies.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Blood Biomarkers of Parenchymal Damage in Ischemic Stroke Patients Treated With Revascularization Therapies

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Currently, anti-ischemic stroke drugs that are in clinical trials or launched mainly include thrombolytic drugs, antiplatelet aggregation drugs, neuroprotective drugs, and drugs promoting angiogenetic effects. 3,4 Among multiple treatment strategies implicated in the pathogenesis of ischemia, neuroprotection is the most attractive protocol. Clinical drugs mainly play a role in different pathophysiological stress processes that mediate brain tissue damage aer ischemic stroke, including vascular dilation and increasing cerebral blood ow, 5,6 antioxidative stress, 7 antiapoptosis, 8 inhibiting excitotoxicity 9 and inhibiting inammation.…”

Section: Introductionmentioning

confidence: 99%

Synthesis and biological evaluation of 2,2-dimethylbenzopyran derivatives as potent neuroprotection agents

Zhou

et al. 2019

RSC Adv.

View full text Add to dashboard Cite

The development of novel neuroprotection agents is of great significance for the treatment of ischemic stroke. In this study, a series of compounds comprising 2,2-dimethylbenzopyran groups and cinnamic acid groups have been synthesized. Preferential combination principles and bioisostere that improved the neuroprotective effect of the compounds were identified for this series via biological activity assay in vitro. Meanwhile, a functional reversal group of the acrylamide amide resulted in the most active compounds. Among them, BN-07 significantly improved the morphology of neurons and obviously increased cell survival rate of primary neurons induced by oxygen glucose deprivation (OGD), superior to clinically used anti-ischemic stroke drug edaravone (Eda). Overall, our findings may provide an alternative strategy for the design of novel anti-ischemic stroke agents with more potency than Eda.

show abstract

Endovascular Therapy for Acute Ischemic Stroke: A Comprehensive Review of Current Status

Cited by 2 publications

References 61 publications

Blood Biomarkers of Parenchymal Damage in Ischemic Stroke Patients Treated With Revascularization Therapies

Blood Biomarkers of Parenchymal Damage in Ischemic Stroke Patients Treated With Revascularization Therapies

Synthesis and biological evaluation of 2,2-dimethylbenzopyran derivatives as potent neuroprotection agents

Contact Info

Product

Resources

About